SG Americas Securities
CRBP icon

SG Americas Securities’s Corbus Pharmaceuticals CRBP Stock Holding History

SG Americas Securities’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,331
Closed -$151K – 3218
2024
Q3 		$151K Buy
+7,331
New +$375K ﹤0.01% 2726
2021
Q2 		– Sell
-353
Closed -$21K – 2911
2021
Q1 		$21K Sell
353
-3,192
-90% -$210K ﹤0.01% 3207
2020
Q4 		$133K Sell
3,545
-37,392
-91% -$1.4M ﹤0.01% 2886
2020
Q3 		$2.21M Buy
40,937
+37,909
+1,252% +$6.87M 0.01% 688
2020
Q2 		$762K Buy
3,028
+2,605
+616% +$526K 0.01% 1681
2020
Q1 		$67K Buy
+423
New +$71.5K ﹤0.01% 3115
2017
Q2 		– Sell
-598
Closed -$148K – 3217
2017
Q1 		$148K Buy
+598
New +$147K ﹤0.01% 2668

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SG Americas Securities's CRBP Position: Q4 2024 in Review

SG Americas Securities sold out of Corbus Pharmaceuticals (CRBP) in Q4 2024, closing a stake of 7,331 shares — an estimated $151K sold.

SG Americas Securities first reported a position in CRBP in Q1 2017 and held it in 7 quarters. The position peaked at $2.21M in Q3 2020. 99 funds tracked by Wall St. Rank hold CRBP as of Q4 2024.

  • SG Americas Securities reported no remaining Corbus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • SG Americas Securities sold 7,331 Corbus Pharmaceuticals shares in Q4 2024, an estimated $151K.
  • SG Americas Securities first reported a position in Corbus Pharmaceuticals in Q1 2017 and held it in 7 quarters.
  • SG Americas Securities's Corbus Pharmaceuticals position peaked at $2.21M in Q3 2020.
  • 99 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2024.

Based on SG Americas Securities's 13F filing for Q4 2024, filed 17 Jan 2025.